191 related articles for article (PubMed ID: 25034059)
1. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease.
Andersson C; Shilane D; Go AS; Chang TI; Kazi D; Solomon MD; Boothroyd DB; Hlatky MA
J Am Coll Cardiol; 2014 Jul; 64(3):247-52. PubMed ID: 25034059
[TBL] [Abstract][Full Text] [Related]
2. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.
Ozasa N; Morimoto T; Bao B; Furukawa Y; Nakagawa Y; Kadota K; Iwabuchi M; Shizuta S; Shiomi H; Tazaki J; Natsuaki M; Kimura T;
Int J Cardiol; 2013 Sep; 168(2):774-9. PubMed ID: 23127614
[TBL] [Abstract][Full Text] [Related]
3. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
Bangalore S; Steg G; Deedwania P; Crowley K; Eagle KA; Goto S; Ohman EM; Cannon CP; Smith SC; Zeymer U; Hoffman EB; Messerli FH; Bhatt DL;
JAMA; 2012 Oct; 308(13):1340-9. PubMed ID: 23032550
[TBL] [Abstract][Full Text] [Related]
4. Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.
Tsujimoto T; Sugiyama T; Kajio H
Diabetes Obes Metab; 2017 Jun; 19(6):800-808. PubMed ID: 28094466
[TBL] [Abstract][Full Text] [Related]
5. Effect of beta-blocker use on outcomes after discharge in patients who underwent cardiac surgery.
Chan AY; McAlister FA; Norris CM; Johnstone D; Bakal JA; Ross DB;
J Thorac Cardiovasc Surg; 2010 Jul; 140(1):182-7, 187.e1. PubMed ID: 20427056
[TBL] [Abstract][Full Text] [Related]
6. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure.
Bunch TJ; Muhlestein JB; Bair TL; Renlund DG; Lappé DL; Jensen KR; Horne BD; Carter MA; Anderson JL;
Am J Cardiol; 2005 Apr; 95(7):827-31. PubMed ID: 15781009
[TBL] [Abstract][Full Text] [Related]
7. Beta-blockers for coronary heart disease in chronic kidney disease.
Chonchol M; Benderly M; Goldbourt U
Nephrol Dial Transplant; 2008 Jul; 23(7):2274-9. PubMed ID: 18187497
[TBL] [Abstract][Full Text] [Related]
8. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial.
Bangalore S; Bhatt DL; Steg PG; Weber MA; Boden WE; Hamm CW; Montalescot G; Hsu A; Fox KA; Lincoff AM
Circ Cardiovasc Qual Outcomes; 2014 Nov; 7(6):872-81. PubMed ID: 25271049
[TBL] [Abstract][Full Text] [Related]
9. Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. The RIMA researchers.
Coletta C; Ricci R; Ceci V; Seccareccia F; Rulli F; Mazzuca V; Putini RL; Salustri A; Bottero G; Pasquale M
G Ital Cardiol; 1999 Feb; 29(2):115-24; discussion 125-9. PubMed ID: 10088066
[TBL] [Abstract][Full Text] [Related]
10. Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention.
Choo EH; Chang K; Ahn Y; Jeon DS; Lee JM; Kim DB; Her SH; Park CS; Kim HY; Yoo KD; Jeong MH; Seung KB
Heart; 2014 Mar; 100(6):492-9. PubMed ID: 24395980
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronotropic incompetence and beta-blocker use on the exercise treadmill test in men.
Gauri AJ; Raxwal VK; Roux L; Fearon WF; Froelicher VF
Am Heart J; 2001 Jul; 142(1):136-41. PubMed ID: 11431669
[TBL] [Abstract][Full Text] [Related]
12. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials.
Beattie WS; Wijeysundera DN; Karkouti K; McCluskey S; Tait G
Anesth Analg; 2008 Apr; 106(4):1039-48, table of contents. PubMed ID: 18349171
[TBL] [Abstract][Full Text] [Related]
13. Extent of heart rate reduction during hospitalization using beta-blockers, not the achieved heart rate itself at discharge, predicts the clinical outcome in patients with acute heart failure syndromes.
Takahama H; Yokoyama H; Kada A; Sekiguchi K; Fujino M; Funada A; Amaki M; Hasegawa T; Asakura M; Kanzaki H; Anzai T; Kitakaze M
J Cardiol; 2013 Jan; 61(1):58-64. PubMed ID: 23165149
[TBL] [Abstract][Full Text] [Related]
14. Health and economic benefits of increased beta-blocker use following myocardial infarction.
Phillips KA; Shlipak MG; Coxson P; Heidenreich PA; Hunink MG; Goldman PA; Williams LW; Weinstein MC; Goldman L
JAMA; 2000 Dec; 284(21):2748-54. PubMed ID: 11105180
[TBL] [Abstract][Full Text] [Related]
15. Beta-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function.
Siu CW; Pong V; Jim MH; Yue WS; Ho HH; Li SW; Lau CP; Tse HF
Pacing Clin Electrophysiol; 2010 Jun; 33(6):675-80. PubMed ID: 20132502
[TBL] [Abstract][Full Text] [Related]
16. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target?
Herman M; Donovan J; Tran M; McKenna B; Gore JM; Goldberg RJ; Tighe DA
Am Heart J; 2009 Sep; 158(3):378-85. PubMed ID: 19699860
[TBL] [Abstract][Full Text] [Related]
17. Discharge heart rate and mortality after acute myocardial infarction.
Seronde MF; Geha R; Puymirat E; Chaib A; Simon T; Berard L; Drouet E; Bataille V; Danchin N; Schiele F
Am J Med; 2014 Oct; 127(10):954-62. PubMed ID: 25004457
[TBL] [Abstract][Full Text] [Related]
18. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.
Vitale C; Iellamo F; Volterrani M; Lombardi M; Fini M; Banach M; Rosano GM
Angiology; 2010 Nov; 61(8):763-7. PubMed ID: 20462892
[TBL] [Abstract][Full Text] [Related]
19. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment?
Wei L; Flynn R; Murray GD; MacDonald TM
Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):761-6. PubMed ID: 15386713
[TBL] [Abstract][Full Text] [Related]
20. Post-myocardial infarction beta-blocker therapy: the bradycardia conundrum. Rationale and design for the Pacemaker & beta-blocker therapy post-MI (PACE-MI) trial.
Goldberger JJ; Bonow RO; Cuffe M; Dyer A; Greenland P; Rosenberg Y; O'Rourke R; Shah PK; Smith S
Am Heart J; 2008 Mar; 155(3):455-64. PubMed ID: 18294477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
